Globalisation of Paediatric Musculoskeletal Matters’ (PMM)

Nicol Smith1, Sharmila Jandial2, Ruth Wylie2, Christine English2, Barbara Davies3, Raju Kubchandani4, Mercedes Chan5, Jane Munro5, Virginia Ferriani5, Claudia Saad Magalhães6, Ricardo Russo5, Jacqueline Yan10, Chris Scott11, Sirirat Charuvanij12, Khulood Khawaja13, Jelena Voinovic14, Charlene Foley15, Tim Rapley16, Helen Foster17

1Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK, 2Paediatric Rheumatology, Great North Children’s Hospital, Newcastle upon Tyne, UK, 3Department of Nursing, Midwifery and Health, Northumbria University, Newcastle Upon Tyne, UK, 4Department of Paediatrics, Jaskol Hospital and Research Center, Mumbai, India, 5Paediatric Rheumatology, University of Alberta, Edmonton, Canada, 6Paediatric Rheumatology, Royal Children’s Hospital, Victoria, Australia, 7Department of Paediatrics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, 8Department of Pediatrics, UNESP, Botucatu, Brazil, 9Service of Immunology/Rheumatology, Hospital de Pediatría Garrahan, Argentina, 10Paediatric Rheumatology, Starship Children’s Health, Auckland, New Zealand, 11Department of Paediatrics, University of Cape Town, Cape Town, South Africa, 12Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand, 13Department of Immunology/Rheumatology, Al-Mafaaj Hospital, Abu Dhabi, United Arab Emirates, 14Paediatric Rheumatology, Faculty of Medicine, University of Nis, Nis, Serbia, 15The National Centre for Paediatric Rheumatology, Our Lady’s Children’s Hospital Crumlin, Dublin, Ireland, 16Social Work, Education & Community Wellbeing, Northumbria University, Newcastle Upon Tyne, UK, 17Newcastle University Medicine Malaysia (NUMed), Newcastle University, Malaysia

Acknowledgements: This work was supported by unrestricted educational bursaries from BioMarin, Sobi, Genzyme and Pfizer.

Background

- ‘paediatric musculoskeletal matters’ (PMM– www.pmmonline.org, (Figure 1)) is a free, evidence-based and peer reviewed open e-resource for paediatric musculoskeletal (MSK) medicine targeting non-MSK specialists [1-3]. Since launch (Nov-2014) PMM has reached 200 countries with >116,700 users, >335,000 hits (data taken June-2018). PMM has been endorsed by PReS as a educational resource for members to aid their teaching to medical students and non-specialists (https://www.pres.eu/activities/scientific-and-clinical/educational-instruments-and-tools.html).
- Registration to PMM is needed to access clinical videos (e.g. pGALS [4,5] demonstrations). Registered users are mainly non-MSK specialists (medical students, primary care and paediatric trainees).
- Feedback from users has requested further content to reflect international healthcare systems. PMM India was developed in collaboration with the Indian Academy of Paediatrics (IAP; Sept-2015, >4,400 users, 17,800 hits to date) and showcases successful partnership with local clinicians in developing PMM with local context.
- Further ‘internationalisation’ with additional global partners to develop ‘PMM International’ to replace the existing PMM site is almost complete. Here, we describe the process for international development.

Methods

- Paediatric rheumatologists around the world were approached to identify additional PMM content to reflect MSK medicine in their healthcare systems (e.g. variation in case mix, clinical presentations, care pathways), with the focus being the level of knowledge relevant for non-MSK specialists.
- New content was developed by local teams identified by the paediatric rheumatologist(s) who then collated and provided expert overview. This new content was submitted for editorial review and peer review.
- The feedback was for the main language for PMM to remain in English with request for pGALS translations.
- Additional cases and images were submitted with appropriate consent.
- The new platform will be free and open to all, and be accessible on the new PReS education website.

Fig 1: PMM homepage – www.pmmonline.org

Results

- Additions to the original PMM website predominately focus on infections / infection-related disease with MSK features or as differential diagnoses for rheumatic disease.
- There were requests for translation of pGALS. The list of languages to be available (so far) is the following:
  - Bulgarian
  - Chinese
  - Indonesian
  - Latvian
  - Lithuanian
  - Portuguese
  - Slovakian
  - Spanish
  - Swedish
  - Thai
  - Turkish
  - Other (please contact us)

- A PMM app is planned to facilitate access where internet capacity is limited. Content and format will be determined in consultation with users.

Conclusions

- Rapid globalisation necessitates appropriate e-resources with content that reflect international healthcare contexts.
- PMM targets non-MSK specialist audiences to raise awareness and early recognition of MSK pathology.
- Our work reflects strong collaborative global partnerships within the paediatric rheumatology community.
- PMM has been endorsed by NICE, RCN and BSPAR; PReS recommends PMM as a resource to be used by specialists to aid their teaching to medical students, primary care and paediatric trainees.
- PMM is available to all as a free resource (and available through the new PReS education website). PMM International will be launched in the upcoming months.
- Implementation of PMM has yet to be formally evaluated, but data so far, supports wide reach and positive uptake with most users being non-specialists.
- PMM-Nursing is now live and targets the learning needs of students and all nurses involved in the care of children and young people – www.pmmonline.org/nurse.

References

5. pGALS app is available (Apple and Google Play – v2018 with language translations). Contact us if you would like to suggest further language translations; h.e.foster@ncl.ac.uk.

Contact us

Email: h.e.foster@ncl.ac.uk
Twitter: @pmm@ncl.ac.uk

PMM-Nursing is also now live and targets the learning needs of students and all nurses involved in the care of children and young people – www.pmmonline.org/nurse.

Acknowledgements: This work was supported by unrestricted educational bursaries from BioMarin, Sobi, Genzyme and Pfizer.

Fig 2: Countries contributing to PMM content – Argentina, Australia, Brazil, Canada, India, New Zealand, Serbia, South Africa, Thailand, UAE, UK to reflect global variation in paediatric rheumatology care and services.

Fig 2: Countries contributing to PMM content – Argentina, Australia, Brazil, Canada, India, New Zealand, Serbia, South Africa, Thailand, UAE, UK to reflect global variation in paediatric rheumatology care and services.

Acknowledgements: This work was supported by unrestricted educational bursaries from BioMarin, Sobi, Genzyme and Pfizer.